Medical News

Short-Duration DAPT Associated with Similar Clinical Outcomes vs. Standard-Duration DAPT Following Second-Generation DES Implantation in ACS Patients

A recent study demonstrated short-duration dual antiplatelet therapy (; ≤6 months) to be associated with a similar incidence of net adverse...

13 Dec, 2018

Email this page
Benefits of Beta-Blockers in a Real-world Contemporary Cohort of ACS Patients, Including those with Mild-Moderate LV Dysfunction

A recent study reaffirmed the benefits of beta-blockers in acute coronary syndrome (ACS) patients. According to the findings of the study, ACS...

07 Dec, 2018

Email this page
Multiple Biomarkers and their association with Risk of All-Cause and Cause-Specific Mortality following ACS-A Secondary analysis of the PLATO Study

Baseline levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and growth differentiation factor-15 (GDF-15) serve as robust markers of...

03 Dec, 2018

Email this page
Tracking the Predictors of Hypertension over a Follow-up Period of 21 Years

Active smoking, being overweight and having increased high-sensitive C-reactive protein increases the risk of incident hypertension by four-folds,...

30 Nov, 2018

Email this page

Key Trials

Sacubitril/Valsartan Improves Physical and Social Activity Limitations in HFrEF Patients

Treatment with sacubitril/valsartan improves physical and social limitations in HFrEF patients in addition to the CV benefits that it provides.

Sacubitril/Valsartan vs. Enalapril in HFrEF Patients: Analyzing the Renal Impact and Associated Outcomes

The study analyzes renal effects and the associated outcomes of sacubitril/valsartan vs. enalapril in HF patients with reduced ejection fraction.  

Treatment with Macitentan Reduces Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension – SERAPHIN Study

Results of the SERAPHIN study demonstrated that treatment with macitentan resulted in significant reduction in morbidity and mortality in patients...

Initiation/Uptitration of Sacubitril/Valsartan in HFrEF Patients: Insights from the TITRATION Trial

The TITRATION trial assessed tolerability of initiating/uptitrating sacubitril/valsartan using a conservative or condensed regimen in HFrEF patients...

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

The Changing Landscape of CV Risk Reduction - Is LDL Lowering Sufficient: Questions & Answers (Dr. Michael Miller, USA)

Here is a set of questions addressed by Dr. Michael Miller, a renowned cardiologist and lipidologist during the “PROMISE” meet held in India.

Pulmonary Hypertension – An Update

This article summarises the definition, classification, pathogenesis, assessment, prognosis, diagnosis and treatment for PH.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Managing Your Angina

It explains the causes, risk factors, symptoms and treatment options for angina, as well as the various do’s and don’t’s in a patient-friendly...

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?
23% (3 votes)
15% (2 votes)
8% (1 vote)
15% (2 votes)
31% (4 votes)
Almost all
8% (1 vote)
Total votes: 13